TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06876649: A Master Protocol to Evaluate the Long-Term Safety of Pirtobrutinib

Sponsor: Eli Lilly and Company · Phase: PHASE4 · Area: ONCOLOGY · Target Enrollment: 787 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$9,609,600

Rescue Site Savings

+$6,357,120

Unlock Full NCT06876649 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06876649 Rescue Dossier →